Analysis of Anti–Vascular Endothelial Growth Factor Injection Claims Data in US Medicare Part B Beneficiaries From 2012 to 2015
Open Access
- 1 August 2019
- journal article
- research article
- Published by American Medical Association (AMA) in JAMA Ophthalmology
- Vol. 137 (8) , 921-928
Abstract
Since the identification of vascular endothelial growth factor (VEGF) as a mediator of retinal and choroidal neovascularization,1,2 anti-VEGF agents have been universally adopted as the first-line treatment for several ocular conditions.3-8 Pegaptanib (an anti-VEGF RNA aptamer) was approved for neovascular age-related macular degeneration (AMD) in 2004.9,10 Approval of bevacizumab (human anti-VEGF) in combination with chemotherapy for colon cancer came in 2004,11-13 with evidence for the use of bevacizumab for neovascular AMD emerging soon after.14,15 This approval coincided with the development of ranibizumab, an anti-angiogenic monoclonal antibody fragment.16 Ranibizumab has been shown to be highly effective for neovascular AMD,17,18 macular edema after branch retinal vein occlusion19,20 and central retinal vein occlusion,21,22 and diabetic macular edema.23,24 Ranibizumab was approved by the US Food and Drug Administration (FDA) for multiple ocular conditions, while use of bevacizumab in ophthalmology remains off-label. Aflibercept, a “VEGF-trap” (an agent that blocks the action of VEGF)25 approved by the FDA in 2011, is likewise effective for AMD,26 macular edema after retinal vein occlusion,27 and diabetic macular edema.28Keywords
This publication has 52 references indexed in Scilit:
- Intravitreal Aflibercept (VEGF Trap-Eye) in Wet Age-related Macular DegenerationOphthalmology, 2012
- Sustained Benefits from Ranibizumab for Macular Edema following Central Retinal Vein Occlusion: Twelve-Month Outcomes of a Phase III StudyOphthalmology, 2011
- Sustained Benefits from Ranibizumab for Macular Edema Following Branch Retinal Vein Occlusion: 12-Month Outcomes of a Phase III StudyOphthalmology, 2011
- Ranibizumab and Bevacizumab for Neovascular Age-Related Macular DegenerationNew England Journal of Medicine, 2011
- Safety and Efficacy of Ranibizumab in Diabetic Macular Edema (RESOLVE Study)Diabetes Care, 2010
- Ranibizumab for Neovascular Age-Related Macular DegenerationNew England Journal of Medicine, 2006
- Pegaptanib, a targeted anti-VEGF aptamer for ocular vascular diseaseNature Reviews Drug Discovery, 2006
- Selection and analysis of an optimized anti-VEGF antibody: crystal structure of an affinity-matured fab in complex with antigen 1 1Edited by I. A. WilsonJournal of Molecular Biology, 1999
- Vascular Permeability Factor, an Endothelial Cell Mitogen Related to PDGFScience, 1989
- Vascular Endothelial Growth Factor Is a Secreted Angiogenic MitogenScience, 1989